Effect of Short-Term Acumagnetotherapy on Diabetic Kidney Disease in Patients with Type II Diabetes and Study on the Molecular Mechanism

Zhou Zi-Yu,Ren Li-Wei,Yang han-Yan,Liu Ji-Zhang,Chu Ke-Dan,Weng Jian-Ping,Yu Zhi-Wen
DOI: https://doi.org/10.1016/s1003-5257(15)30056-8
2015-01-01
Abstract:Objective To explore whether magnetotherapy is preventive in retarding diabetic kidney disease (DKD) progression and investigate underling molecular mechanismsrelated to its therapeutic efficacy. Methods Twenty-eight patients with type II diabetes (T2D) were undergone pulsed electromagnetic fields (PEMF) stimulation at the acupoints of pishu (BL 20), Zusanli (ST 36), Shenshu (BL 23) and Yishu (EX-B3) for a period of 4 weeks. Urinary micro-albumin (U-mAlb) excretion, plasma methane dicarboxylic aldehyde (MDA and lipopolysaccharide (LPS) of the patients were used for evaluating therapeutic efficacies. Results After the acumagnetotherapy, U-mAlb excretion in the participated patients was markedly reduced (27.21 +/- 3.51 vs 8.51 +/- 0.95, P< 0.001) accompanied with decreased MOA (16.46 +/- 1.17 vs 12.40 +/- 1.86, P< 0.05) and LPS (37.41 +/- 3.84 vs 21.63 +/- 3.61, P<0.05) levels in plasma while the metabolic control of these patients was not significantly altered. Acumagnetotherapy increased IKBa content (0.69 +/- 1.17 vs 1.30 +/- 0.29, P<0.01), an inhibitory protein of inflammatory response, and correspondingly reduced the protein levels of inflammatory activating proteins, NF-B-K p65 (0.98 +/- 0.42vs 0.43 +/- 0.28, P<0.05) and NF-B-K p50 (1.19 +/- 0.40 vs 0.76 +/- 0.30, P<0.05). The acumagnetotherapy also inhibited the oxidantproducing enzyme, Nox4 protein expression (1.32 +/- 0.40 vs 0.37 +/- 0.23, P<0.05) in patient's blood lymphocytes. Conclusion Short-term intervention of acumagnetotherapy in patients with T2D mitigates DKD progress potentially by its anti- oxidative and anti-inflammatory effects.
What problem does this paper attempt to address?